On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

Hims & Hers Health, Inc. (HIMS) announced on Wednesday that it will expand to Canada next year with its weight loss program, ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Investors, CEOs and commentators trashed Hims & Hers founder and CEO Andrew Dudum on social media Wednesday after he praised the "moral courage" of the anti-Israel protesters creating havoc on ...

Andrew Dudum is a disrupter. In 2017 he founded Hims & Hers (NYSE: HIMS), a digital health startup with the goal of upending the traditional healthcare market.

Kevin O'Leary sounded off on Hims & Hers CEO Andrew Dudum over his initial support of the anti-Israel protests and said he would have been fired in seconds if he worked for him.

Hims & Hers co-founder and CEO Andrew Dudum spoke on potentially getting into the glucagon-like peptide agonists, or GLP-1, weight loss drug market, how much the company spends marketing to ...

Andrew Dudum, the Palestinian American CEO of Hims, a telehealth and online pharmacy known for its suggestive New York City subway ads, shared a link to current openings and encouraged the student ...